Abstract

Simple SummaryLimited therapeutic results of immune checkpoint inhibitors in definite tumor settings, such as melanoma, call for alternative or complementary approaches. Among these, adoptive cell therapy (ACT) by means of HLA-independent tumor killer lymphocytes is a promising approach. We aimed at developing a pre-clinical 3D model to investigate and visualize the interaction between tumor and immune effectors in melanoma. To this aim, we employed Cytokine-Induced Killer cells (CIK) and NK-92 on patient-derived melanoma samples. By means of imaging-based methods, we measured the effector recruitment on the 3D targets, their infiltration, and cytotoxic activity. Our results and methodologies can be easily generalized to other effectors and other classes of tumors and help elucidate fundamental questions on the basic biology and kinetics of immune effector recruitment in a realistic 3D setting mimicking a solid tumor.Cancer adoptive cell therapy (ACT) with HLA-independent tumor killer lymphocytes is a promising approach, with intrinsic features potentially addressing crucial tumor-escape mechanisms of checkpoint inhibitors. Cytokine-induced Killer (CIK) and Natural Killer (NK) lymphocytes share similar tumor-killing mechanisms, with preclinical evidence of intense activity against multiple solid tumors and currently testing in clinical studies. To improve the effective clinical translation of such ACT approaches, several fundamental questions still need to be addressed within appropriate preclinical contexts, capable of overcoming limitations imposed by most traditional two-dimensional assays. Here, we developed a novel experimental approach to explore, dissect, and visualize the interactions of CIK and NK lymphocytes with melanoma tumors in vitro in 3D. Primary melanoma cells were assembled into small tumors that were dispersed in a 3D matrix and challenged with patient-derived CIK or the NK-92 cell line. By means of imaging-based methods, we reported, visualized, and quantitatively measured the recruitment of CIK and NK on the 3D targets, their infiltration, and cytotoxic activity. Our results support the effective tumor recruitment and tumor infiltration by CIK and NK. Such features appeared dependent on the specific geometric aspects of the environment but can be explained in terms of directional migration toward the tumor, without invoking major feedback components. Overall, our 3D platform allows us to monitor the processes of tumor recruitment, infiltration, and killing by means of live measurements, revealing important kinetic aspects of ACT with CIK and NK against melanoma.

Highlights

  • Cancer immunotherapy is widely impacting and improving oncological treatments and patients’ outcome

  • In order to dissect the different steps characterizing the interactions between killer lymphocytes and cancer cells in an adoptive cell therapy (ACT) setting, we set up a 3D coculture method

  • We exploited a previously established tumor sample biobank, which features cell lines obtained from eight surgical samples derived from metastatic melanoma

Read more

Summary

Introduction

Cancer immunotherapy is widely impacting and improving oncological treatments and patients’ outcome. Immune checkpoint inhibitors (CI), capable of overcoming tumor adaptive resistance and restoring effective T cell-mediated immune responses, currently dominate the therapeutic scenario [1,2,3,4,5]. Even acknowledging these important achievements, a relevant rate of patients still may not benefit from CI and refractory/relapsing diseases remain important issues and challenges for clinicians and researchers [1,6,7,8]. Cancer adoptive cell therapy (ACT) is emerging as an intriguing strategy, holding promises as an alternative or integrative approach in tumor settings poorly responding to CI. The great potential of these approaches is sustained by multiple preclinical evidence and initial clinical data [13,14,15,16]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call